EB Pharma Developments
ActiveSummary
EB Pharma Developments has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €5,298 and a net result of -€1,347. Equity is shrinking by ~27% per year and would, assuming unchanged policy, indicatively turn negative around fiscal year 2027. Its solvency ranks better than 40% of 779 sector peers (NACE 74, fiscal year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Financials · fiscal year 2025, abbreviated schema
2022 to 2025, 4 fiscal years
The operating result turns negative in 2025: a loss of €1,589 after €3,300 in 2024.
What the company sold each fiscal year and what was left of it. A loss stands below the zero line.
What the company owns (total assets), how much of it is its own (equity) and how much it owes.
Short-term assets minus short-term debts. Above zero the company can pay its bills in the short term.
How much of each euro of turnover is left from operations (EBIT margin) and what the assets earn (return on assets).
The share of the company financed with its own means. The higher it is, the better it absorbs a shock.
Short-term assets per euro of short-term debt. Above 1 the short-term debts are covered.
Point at or tap a year, or use the arrow keys on the chart, for the exact figures; the table below gives them all.Sector: the middle half (P25 to P75) of NACE 74, Other professional, scientific and technical activities, each year against the same schema; no band under 30 filings. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA).
Peer companies
Historical observationOf the 2,146 companies that looked in July 2024 the way this one looks now, 2.2% went bankrupt within 24 months and 92% are still going.
- Micro
- 2 to 5 years old
- solvency 30% or more
- a small loss
A further 0.2% stopped, but we cannot tell whether within those 24 months.
For this company itself Checked computes a lower bankruptcy probability: 0.1% over twelve months. The score reads more about this company than the group's four characteristics; both figures are right about what they measure.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,471 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 1.0% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 2,146 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
| Line | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|
| Other operating charges640/8 | €348 | €446 | €449 | €462 | ▲ 2.8% |
| Gross operating margin9900 | €20,964 | -€4,297 | €3,749 | -€1,127 | ▼ 130% |
| Operating profit (loss)9901 | €20,616 | -€4,744 | €3,300 | -€1,589 | ▼ 148% |
| Financial income75/76B | - | €196 | €1,675 | €364 | ▼ 78.2% |
| Recurring financial income75 | - | €196 | €1,675 | €364 | ▼ 78.2% |
| Financial charges65/66B | €79 | €97 | €1,408 | €123 | ▼ 91.3% |
| Recurring financial charges65 | €79 | €97 | €1,408 | €123 | ▼ 91.3% |
| Profit (loss) for the period before taxes9903 | €20,537 | -€4,644 | €3,567 | -€1,347 | ▼ 138% |
| Income taxes67/77 | €4,316 | €0 | - | - | - |
| Profit (loss) for the period9904 | €16,222 | -€4,644 | €3,567 | -€1,347 | ▼ 138% |
| Profit (loss) for the period to be appropriated9905 | €16,222 | -€4,644 | €3,567 | -€1,347 | ▼ 138% |
| Line | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|
| Assets | |||||
| Total assets20/58 | €22,037 | €13,078 | €19,064 | €16,951 | ▼ 11.1% |
| Current assets29/58 | €22,037 | €13,078 | €19,064 | €16,951 | ▼ 11.1% |
| Amounts receivable within one year40/41 | €9,555 | €8,378 | €9,445 | €8,215 | ▼ 13.0% |
| Trade receivables40 | - | €823 | €3,880 | €0 | ▼ 100% |
| Other amounts receivable41 | €9,555 | €7,555 | €5,565 | €8,215 | ▲ 47.6% |
| Cash at bank and in hand54/58 | €12,482 | €4,700 | €9,619 | €8,736 | ▼ 9.2% |
| Equity and liabilities | |||||
| Total equity and liabilities10/49 | €22,037 | €13,078 | €19,064 | €16,951 | ▼ 11.1% |
| Equity10/15 | €17,722 | €13,078 | €16,645 | €5,298 | ▼ 68.2% |
| Contributions10/11 | €1,500 | €1,500 | €1,500 | €1,500 | = |
| Reserves13 | €16,222 | €11,578 | €15,145 | €3,798 | ▼ 74.9% |
| Distributable reserves133 | €16,222 | €11,578 | €15,145 | €3,798 | ▼ 74.9% |
| Profit (loss) carried forward14 | - | - | - | €0 | - |
| Amounts payable17/49 | €4,316 | €0 | €2,420 | €11,654 | ▲ 382% |
| Amounts payable within one year42/48 | €4,316 | €0 | €2,420 | €11,654 | ▲ 382% |
| Trade debts44 | - | - | €1,920 | €636 | ▼ 66.9% |
| Suppliers440/4 | - | - | €1,920 | €636 | ▼ 66.9% |
| Taxes, remuneration and social security45 | €4,316 | €0 | - | - | - |
| Taxes450/3 | €4,316 | €0 | - | - | - |
| Other amounts payable47/48 | - | - | €500 | €11,018 | ▲ 2,104% |
| Line | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €16,222 | -€4,644 | €3,567 | -€1,347 | ▼ 138% |
| Operating cash flow (approximation) | €16,222 | -€4,644 | €3,567 | -€1,347 | ▼ 138% |
| Change in cash | - | -€7,782 | €4,919 | -€883 | ▼ 118% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.